SLN Silence Therapeutics Plc

  1. Stocks
  2. Healthcare
  3. NASDAQ: SLN

Price (delayed)

$11.51

Market cap

$543.27M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.32

Enterprise value

$471.32M

?
Relative Growth: Rel. Growth: 12
Relative Strength: Rel. Strength: 96
Relative Valuation: Rel. Valuation: 1
Relative Profitability: Rel. Profitability: 25
Highlights
The equity has soared by 59% YoY and by 22% from the previous quarter
Silence Therapeutics's net income has increased by 24% YoY and by 20% from the previous quarter
SLN's revenue has plunged by 98% YoY and by 27% from the previous quarter
The gross profit has plunged by 98% YoY and by 21% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Peers: ALNY NTLA IONS MRNA

Key stats

What are the main financial stats of SLN

SLN stock price

How has the Silence Therapeutics stock price performed over time
Intraday
-6.35%
1 week
-7.92%
1 month
-13.26%
1 year
123.5%
YTD
89.31%
QTD
4.83%

Financial performance

How have Silence Therapeutics's revenue and profit performed over time
Revenue
$615,000
Gross profit
$528,000
Operating income
-$68.31M
Net income
-$59.95M
Gross margin
85.9%
Net margin
-9,748.5%
SLN's revenue has plunged by 98% YoY and by 27% from the previous quarter
The gross profit has plunged by 98% YoY and by 21% from the previous quarter
Silence Therapeutics's net income has increased by 24% YoY and by 20% from the previous quarter
SLN's operating income is up by 21% YoY and by 13% QoQ

Price vs fundamentals

How does SLN's price correlate with its fundamentals

Growth

What is Silence Therapeutics's growth rate over time

Valuation

What is Silence Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
883.17
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
766.38
Silence Therapeutics's EPS has increased by 20% YoY and by 19% QoQ
The equity has soared by 59% YoY and by 22% from the previous quarter
The P/S is 127% higher than the last 4 quarters average of 415.4
SLN's revenue has plunged by 98% YoY and by 27% from the previous quarter

Efficiency

How efficient is Silence Therapeutics business performance
SLN's ROA is down by 16% YoY but it is up by 11% from the previous quarter
SLN's ROIC is down by 14% YoY and by 10% from the previous quarter
Silence Therapeutics's return on sales has decreased by 9% QoQ

Dividends

What is SLN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SLN.

Financial health

How did Silence Therapeutics financials performed over time
The total assets is 57% more than the total liabilities
The total assets has contracted by 36% YoY and by 8% from the previous quarter
Silence Therapeutics's quick ratio has decreased by 27% YoY and by 15% QoQ
Silence Therapeutics's debt is 100% more than its equity
The equity has soared by 59% YoY and by 22% from the previous quarter
Silence Therapeutics's debt has decreased by 18% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.